Phagocytic Uptake and Cytotoxicity of Solid Lipid Nanoparticles (SLN) Sterically Stabilized with Poloxamine 908 and Poloxamer 407

Müller, Rainer H.; Maaben, S.; Weyhers, H; Mehnert, W.

doi:10.3109/10611869609015973

Cited by 198 publications

(93 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the mixture accommodates the drug in molecular form or in amorphous clusters (Muller et al, 2007). The lipids employed in these are usually biocompatible and biodegradable with low toxicity as opposed to the polymeric nanoparticles (Muller et al, 1996;Kumar, 2000). NLCs show high drug loading for both lipophilic and hydrophilic drugs, also promote oral absorption of encapsulated drug via selective uptake through lymphatic route or payer's patches (Fundaro et al, 2000;Chen et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

et al. 2016

View full text Add to dashboard Cite

The purpose of this study was to develop Carvedilol nanostructured lipid carriers (CAR-NLCs) using stearic acid and oleic acid as lipid, and to estimate the potential as oral delivery system for poorly water soluble drug. The particle-size analysis revealed that all the developed formulations were within the nanometer range. The EE and loading were found to be between 69.45-88.56% and 9.58-12.56%, respectively. The CAR-NLCopt showed spherical morphology with smooth surface under transmission electron microscope (TEM). The crystallization of the drug in NLC was investigated by powder X-ray diffraction and differential scanning calorimetry (DSC) and revealed that the drug was in an amorphous state in the NLC matrix. The ex vivo gut permeation study showed many folds increment in the permeation of CAR-NLCs compared to Carvedilol suspension (CAR-S). The oral bioavailability study of CAR was carried out using Wistar rats and relative bioavailability of CAR-NLCopt was found to be 3.95 fold increased in comparison with CAR-S. In vivo antihypertensive study in Wistar rats showed significant reduction in mean systolic BP by CAR-NLCopt vis-à-vis CAR-S (p50.05) owing to the drug absorption through lymphatic pathways. In conclusion, the NLC formulation remarkably improved the oral bioavailability of CAR and demonstrated a promising perspective for oral delivery of poorly water-soluble drugs. The promising findings in this investigation suggest the practicability of these systems for the enhancement of bioavailability of CAR.

show abstract

Section: Introductionmentioning

confidence: 99%

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Due to the increasing attention towards lipid-based drug delivery systems, American Association of Pharmaceutical Scientists has formed a "Lipid-Based Drug Delivery Systems Focus Group" (www.aaps.org/inside/ focus_groups/Lipid). The lipids employed to prepare lipid nanoparticles are usually physiological lipids (biocompatible and biodegradable) with low acute and chronic toxicity (5). In case of polymeric nanoparticles, the in vivo degradation of the polymer might cause toxic effects (5,6).…”

Section: Introductionmentioning

confidence: 99%

“…The lipids employed to prepare lipid nanoparticles are usually physiological lipids (biocompatible and biodegradable) with low acute and chronic toxicity (5). In case of polymeric nanoparticles, the in vivo degradation of the polymer might cause toxic effects (5,6). Lipid nanoparticles adopted the best features of other colloidal carriers, such as polymeric nanoparticles, liposomes, conventional oilin-water emulsions, and nanoemulsions (7).…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery

2010

View full text Add to dashboard Cite

Abstract. Lipid nanoparticles based on solid matrix have emerged as potential drug carriers to improve gastrointestinal (GI) absorption and oral bioavailability of several drugs, especially lipophilic compounds. These formulations may also be used for sustained drug release. Solid lipid nanoparticle (SLN) and the newer generation lipid nanoparticle, nanostructured lipid carrier (NLC), have been studied for their capability as oral drug carriers. Biodegradable, biocompatible, and physiological lipids are generally used to prepare these nanoparticles. Hence, toxicity problems related with the polymeric nanoparticles can be minimized. Furthermore, stability of the formulations might increase than other liquid nano-carriers due to the solid matrix of these lipid nanoparticles. These nanoparticles can be produced by different formulation techniques. Scaling up of the production process from lab scale to industrial scale can be easily achieved. Reasonably high drug encapsulation efficiency of the nanoparticles was documented. Oral absorption and bioavailability of several drugs were improved after oral administration of the drugloaded SLNs or NLCs. In this review, pros and cons, different formulation and characterization techniques, drug incorporation models, GI absorption and oral bioavailability enhancement mechanisms, stability and storage condition of the formulations, and recent advances in oral delivery of the lipid nanoparticles based on solid matrix will be discussed.

show abstract

“…Selection of magnetic nanoparticles for this research was a challenging task because of toxic character of some magnetic nanoparticles. Most of the research on magnetic nanoparticles for clinical applications has focused on iron oxide nanoparticles such as magnetite (Fe 3 O 4 ) or maghemite (γ-Fe 2 O 3 ) dDue to their biological compatibility and FDA approval for clinical usage (Weissleder et al 1989;Ibrahim et al 1983;Muller et al 1996;Andujar et al 2012), magnetite was used in this study. In this study, oleic acidcoated magnetite (Fe 3 O 4 ) nanoparticles were selected, because they are well dispersible in organic media.…”

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: Part II. Effect of process variables on protein model drug encapsulation efficiency

Shubhra

Feczkó

Kardos

et al. 2013

Journal of Microencapsulation

View full text Add to dashboard Cite

This study investigates encapsulation efficiency of model drug, encapsulated by magnetic PLGA (poly D,L-lactic-co-glycolic acid) nanoparticles (NPs). This is the following part of our preceding paper, which is referred in this paper as Part I. Magnetic nanoparticles and model drug human serum albumin (HSA) loaded PLGA NPs were prepared by double emulsion solvent evaporation method. Among five important process variables, concentration of PLGA and concentration of HSA in the inner aqueous phase Encapsulation efficiency of nanoparticles ranged from 18 to 97% depending on the process conditions. Higher encapsulation efficiencies can be achieved by using low HSA and high PLGA concentrations. The optimization process, carried out by exact mathematical tools using GAMS TM /MINOS software makes it easier to find out optimum process conditions to achieve comparatively high encapsulation efficiency (e.g. 92.3%)for relatively small sized PLGA NPs (e.g. 155 nm).

show abstract

Phagocytic Uptake and Cytotoxicity of Solid Lipid Nanoparticles (SLN) Sterically Stabilized with Poloxamine 908 and Poloxamer 407

Cited by 198 publications

References 14 publications

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery

Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: Part II. Effect of process variables on protein model drug encapsulation efficiency

Contact Info

Product

Resources

About